88887-87-0

Basic information

• Product Name: 1-Methylcyclopropylamine hydrochloride
• Synonyms: 1-Methylcyclopropylamine hydrochloride;1-MethylcyclopropanaMine hydrochloride;1-aMino-1-Methylcyclopropane hydrochloride;CyclopropanaMine,1-Methyl-, hydrochloride (1:1);1-Methylcyclopropan-1-amine hydrochloride;(1-Methylcyclopropyl)aMine hydrochloride (SALTDATA: HCl);1-Methylcyclopropanamine HCl;1-Methylcyclopropanaminium chloride
• CAS NO: 88887-87-0
• Molecular Formula: C₄H₉N*ClH
• Molecular Weight: 107.5819
• Mol File: 88887-87-0.mol
• Article Data: 12

Chemical Properties

• Melting Point: 204-205 °C(Solv: ethyl acetate (141-78-6); methanol (67-56-1))
• Boiling Point: 112 °C at 760 mmHg
• Flash Point: 21.5 °C
• Appearance: /
• Vapor Pressure: 20.4mmHg at 25°C
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 1-Methylcyclopropylamine hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Methylcyclopropylamine hydrochloride(88887-87-0)
• EPA Substance Registry System: 1-Methylcyclopropylamine hydrochloride(88887-87-0)

Safety Data

• Hazardous Substances Data: 88887-87-0(Hazardous Substances Data)

Usage

General Description

1-Methylcyclopropylamine hydrochloride is a chemical compound consisting of a cyclopropylamine molecule with a methyl group attached to one of its carbon atoms, and a hydrochloride salt. 1-Methylcyclopropylamine hydrochloride is commonly used in organic synthesis and pharmaceutical research as a building block for the production of various organic compounds and medications. It is known for its ability to react with other molecules to form a wide variety of chemical compounds. Furthermore, the hydrochloride salt form of this compound improves its solubility in water, making it easier to handle and use in laboratory settings. Additionally, 1-Methylcyclopropylamine hydrochloride is used in the production of pesticides, herbicides, and other agrochemicals due to its favorable chemical properties.

InChI:InChI=1/C4H9N.ClH/c1-4(5)2-3-4;/h2-3,5H2,1H3;1H

Upstream product

• 67-64-1 acetone 
• 74-96-4 ethyl bromide 
• 75-05-8 acetonitrile 
• 119111-67-0 N-bromo-1-methylcyclopropanecarboxamide 
• 251661-01-5 1,1-dimethylethyl (1-methylcyclopropyl)carbamate 
• 6914-76-7 1-Methyl-cyclopropanoic acid 

Downstream Products

• 22936-83-0 (1-methylcyclopropyl)amine 
• 113220-22-7 (Z)-3-(1-Methyl-cyclopropylamino)-2-(2,3,4,5-tetrafluoro-benzoyl)-acrylic acid ethyl ester 
• 279215-43-9 6-chloro-3-(1-methylcyclopropyl)amino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide 
• 365996-75-4 5-(1-methyl-cyclopropyl)-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine 
• 812639-90-0 methyl-phenyl-carbamic acid 5-[3-(1-methyl-cyclopropyl)-thioureido]-pyridin-2-yl ester 
• 851847-88-6 4-methyl-N-(1-methylcyclopropyl)-3-nitrobenzamide 
• 1215105-31-9 4-fluoro-2-(4-fluorophenyl)-5-(4-methoxy-2-methyl-5-(1-methylcyclopropylcarbamoyl)phenyl)-N-methylpyrazolo[1,5-a]pyridine-3-carboxamide 
• 1260842-08-7 (R)-5-(2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl)-N-(1-methylcyclopropyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide 
• 1403865-31-5 5-bromo-N-(1-methylcyclopropyl)-4-(methylthio)pyrimidin-2-amine 
• 1614246-95-5 N-(3,5-dichloropyridazin-4-yl)-N'-(1-methylcyclopropyl)imidoformamide 
• 58102-14-0 1-(1-methylcyclopropyl)urea 

Relevant articles and documents

INDAZOLE DERIVATIVES USEFUL AS PERK INHIBITORS

The invention is directed to substituted indazole derivatives and uses thereof. Specifically, the invention is directed to compounds according to Formula I and the use of compounds of Formula (I) in treating disease states (I) wherein R1, R2, R3, R4, R5, are as defined herein; or a salt thereof including a pharmaceutically acceptable salt thereof. The compounds of the invention are inhibitors of PERK and can be useful in the treatment of cancer, pre-cancerous syndromes and diseases associated with activated unfolded protein response pathways, such as Alzheimer's disease, spinal cord injury, traumatic brain injury, ischemic stroke, stroke, Parkinson disease, diabetes, metabolic syndrome, metabolic disorders, Huntington's disease, Creutzfeldt-Jakob Disease, and related prion diseases, fatal familial insomnia, Gerstmann-Straussler-Scheinker syndrome, and related prion diseases, amyotrophic lateral sclerosis, progressive supranuclear palsy, myocardial infarction, cardiovascular disease, inflammation, organ fibrosis, chronic and acute diseases of the liver, fatty liver disease, liver steatosis, liver fibrosis, chronic and acute diseases of the lung, lung fibrosis, chronic and acute diseases of the kidney, kidney fibrosis, chronic traumatic encephalopathy (CTE), neurodegeneration, dementias, frontotemporal dementias, tauopathies, Pick's disease, Neimann-Pick's disease, amyloidosis, cognitive impairment, atherosclerosis, ocular diseases, neurological disorders, pain, arrhythmias, in organ transplantation and in the transportation of organs for transplantation. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting PERK activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

2,4-DIOXO-QUINAZOLINE-6-SULFONAMIDE DERIVATIVES AS INHIBITORS OF PARG

The present invention relates to compounds of formula I that function as inhibitors of PARG (Poly ADP-ribose glycohydrolase) enzyme activity wherein R1a, R1b, R1c, R1d, R1e, W, X1, X2, X3, X4, X5, X6, X7, c are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which PARG activity is implicated.

SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS

Compounds of Formula (I) and salts thereof in which R1, R2, R3, R4, X, Y and n have the meanings given in the specification, are inhibitors of Trk kinases and are useful in the treatment of diseases which can be treated with a Trk kinase inhibitor such as pain, cancer, inflammation, neurodegenerative diseases and certain infectious diseases.